Pyridine nucleotides in glucose metabolism and diabetes: A review

Diabetes/Metabolism Research and Reviews

Volumn 16, Issue 1, 2000, Pages 33-42

  Wahlberg, Gustaf ^a,c   Adamson, Ulf ^a   Svensson, Jan ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b DANDERYD HOSPITAL   (Sweden)

^c Serafen Health Centre   (Sweden)

Author keywords

Diabetes; Glucose metabolism; Microangiopathy; NAD; Nicotinamide; Nicotinic acid

Indexed keywords

GLUCOSE; INSULIN RECEPTOR; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NICOTINIC ACID; PHOSPHATE; PYRIDINE NUCLEOTIDE; PYRUVIC ACID; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SORBITOL;

DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; GLUCOSE METABOLISM; GLUCOSE UTILIZATION; HUMAN; HYPERGLYCEMIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; THEORY;

ANIMALS; DIABETES MELLITUS; GLUCOSE; HUMANS; NAD; NADP; REFERENCE VALUES;

EID: 0034061147     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-7560(200001/02)16:1<33::AID-DMRR79>3.0.CO;2-S     Document Type: Review

References (109)

1. Lehninger AL, Nelson DL, Cox MM. In Principles of Biochemistry 2, Chapter 5. New York, NY, Worth, 1993.
2. Fraser IM. Effect of mechlorethamine on tumor glycolysis and diphosphopyridine nucleotide content. Fed Proc 1960; 19: 395
3. Holzer H, Boltze HJ. Effect of nicotinamide on inhibition of ascites tumor cell glycolysis by ethyleneimine derivatives. Z Krebsforsch 1961; 64: 113-121.
4. Roitt IM. Inhibition of carbohydrate metabolism in ascites tumor cells by ethyleneimines. Biochem J 1956; 63: 300-307.
5. Schmidt CG. Relationship between diphosphopyridine nucleotide (DPN) concentration and inhibition of tumor cell glycolysis by carzinophilin. Z Krebsforsch 1961; 64: 156-168.
6. Schein PS, Cooney DA, Vernon ML. The use of nicotinamide to modify the toxicity of streptozotocin diabetes without loss of antitumor activity. Cancer Res 1967; 27: 2324-2332.
7. Grunewald RW, Weber II, Kinne-Saffran E, Kinne RKH. Control of sorbitol metabolism in renal inner medulla of diabetic rats: regulation by substrate, cosubstrate and products of the aldose reductase reaction. Biochim Biophys Acta 1993; 1225: 39-47.
8. Bravi MC, Pietrangeli P, Laurenti O, Basili S, Cassone-Faldetta M, Ferri C, De Mattia G. Polyol pathway activation and glutathione redox status in non-insulin-dependent diabetic patients. Metabolism 1997; 46: 1194-1198.
9. Williamson JR, Chang K, Frangos M, et al. (Perspective in diabetes). Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993; 42: 801-813.
10. +. Kidney Int 1992; 41: 778-788.
11. Van den Enden MK, Nyengaard JR, Ostrow E, Burgan JH, Williamson JR. Elevated glucose levels increase retinal glycolysis and sorbitol pathway metabolism. Implications for diabetic retinopathy. Invest Opthalmol Vis Sci 1995; 36: 1675-1685.
12. Kaplan NO, Goldin A, Humphreys SR, Ciotti MM, Stolzenbach FE. Pyridine nucleotide synthesis in the mouse. J Biol Chem 1956; 219: 287-298.
13. Revel M, Mandel P. Effect of an induced synthesis of pyridine nucleotides in vivo in the metabolism of ribonucleic acid. Cancer Res 1962; 22: 456-462.
14. Streffer C, Brauer W, Benes J. Levels of pyridine nucleotides after repeated applications of nicotinic acid in animal tissues. In Metabolic Effects of Nicotinic Acid and its Derivatives. Gey KF, Carlson LA (eds). Bern: Hans Huber Verlag, 1971; 97-114.
15. + level of blood, liver, adipose tissue and aorta during hyperlipemic conditions. In Metabolic Effects of Nicotinic Acid and its Derivatives. Gey KF, Carlson LA (eds). Bern: Hans Huber Verlag, 1971; 115-122.
16. McCreanor GM, Bender DA. The metabolism of high intakes of tryptophan, nicotinamide and nicotinic acid in the rat. Br J Nutr 1986; 56: 577-586.
17. Root MA, Ashmore J. The hypoglycemic activity of nicotinic acid in rats. Naunyn-Schmiedebergs Arch Exp Path u Pharmak 1964; 248: 117-123.
18. Lassers BW, Wahlqvist ML, Kaijser L, Carlson LA. Relationship in man between plasma free fatty acids and myocardial metabolism of carbohydrate substrates. Lancet 1971; ii: 448-458.
19. Ammon HPT, Estler C-J, Heim F. Alteration of carbohydrate metabolism in liver, skeletal muscle and brain by nicotinic acid in mice. In Metabolic Effects of Nicotinic Acid and its Derivatives. Gey KF, Carlson LA (eds). Bern: Hans Huber Verlag, 1971; 799-809.
20. Kaijser L, Nye ER, Eklund B, Olsson AG, Carlson LA. The relation between carbohydrate extraction by the forearm and arterial free fatty acid concentration in man. Scand J Clin Lab Invest 1978; 38: 41-47.
21. Bergström J, Hultman E, Jorfeldt L, Pernow B, Wahren J. Effect of nicotinic acid on physical working capacity and on metabolism of muscle glycogen in man. J Appl Physiol 1969; 26: 170-176.
22. Hasselblatt A, Panten U, Poser W. Effects of antilipolytic compounds on hepatic and renal gluconeogenesis in the rat. In Metabolic Effects of Nicotinic Acid and its Derivatives. Gey KF, Carlson LA (eds). Bern: Hans Huber Verlag, 1971; 879-884.
23. Lee HM, Ellis RM, Sigal MV Jr. Some insulin-like effects of nicotinic acid observed with isolated rat epididymal adipose tissue. Biochim Biophys Acta 1961; 49: 408-410.
24. Shafrir E, Orevi M, Gutman A. Effect of nicotinic acid on carbohydrate metabolism in adipose tissue. In Metabolic Effects of Nicotinic Acid and its Derivatives. Gey KF, Carlson LA (eds). Bern: Hans Huber Verlag, 1971; 763-771.
25. Reaven GM, Chang H, Ho H, Jeng C-Y, Hoffman BB. Lowering of plasma glucose in diabetic rats by antilipolytic agents. Amer J Physiol 1988; 254 (Endocrinol Metab 17): E23-E30.
26. Wahlberg G. Effects of nicotinic acid on lipoprotein, fatty acid and glucose metabolism in patients with hyperlipoproteinemia. Thesis. Stockholm: Reproprint AB, 1993.
27. Wahlberg G, Walldius G, Efendic S. Effects of nicotinic acid treatment on glucose tolerance and glucose incorporation into adipose tissue in hypertriglyceridemia. Scand J Clin Lab Invest 1992; 52: 537-455.
28. Wahlberg G, Walldius G. Effects of nicotinic acid treatment on glyceride formation and lipolysis in adipose tissue of hyperlipidemic patients. Int J Clin Lab Res 1993; 23: 88-94.
29. Carlson LA, Eriksson I, Walldius G. A case of massive hypertriglyceridaemia and impaired fatty acid incorporation into adipose tissue glycerides (FIAT), both corrected by nicotinic acid. Acta Med Scand 1973; 194: 363-369.
30. Bizzi A, Garattini S. Drugs lowering plasma free fatty acids: similarities and dissimilarities with nicotinic acid effect. In Metabolic Effects of Nicotinic Acid and its Derivatives. Gey KF, Carlson LA (eds), Bern: Hans Huber Verlag, 1971; 207-220.
31. Miettinen TA, Taskinen M-R, Pelkonen R, Nikkilä EA. Glucose tolerance and plasma insulin in man during acute and chronic administration of nicotinic acid. Acta Med Scand 1969; 186: 247-253.
32. Wahlberg G, Carlson LA, Wasserman J, Ljungqvist A. Protective effect of nicotinamide against nephropathy in diabetic rats. Diabetes Res 1985; 2: 307-312.
33. Hotta N, Kakuta H, Fukasawa H, et al. Effect of niceritrol on streptozotocin-induced diabetic neuropathy in rats. Diabetes 1992; 41: 587-591.
34. Handfield-Jones S. High dose nicotinamide in the treatment of necrobiosis lipoidica. Br J Dermatol 1988; 118: 693-696.
35. Rhodes EL. Fibrinolytic agents in the treatment of necrobiosis lipoidica. Angiology 1978; 29: 60-64.
36. Rose IA, Rose ZB. Glycolysis: regulation and mechanisms of the enzymes. In Comprehensive Biochemistry. Florkin M, Stotz EH (eds). Amsterdam, London, New York: Elsevier Publishing Company, 1969; 93-161.
37. Ishihara A, Sudo J, Tanabe T. Inhibition of glucose reabsorbtion induced by 6-aminonicotinamide in the rat kidney. J Toxicol Sci 1984; 9: 353-362.
38. Ammon HPT, Steinke J. 6-aminonicotinamide (6-AN) as a diabetogenic agent. In vitro and in vivo studies in the rat. Diabetes 1972; 21: 143-148.
39. Ammon HPT, Steinke J. Inhibition of the pentose-phosphate shunt and insulin release in isolated pancreatic rat islets by 6-aminonicotinamide. Fed Proc 1971; 30: 249
40. Velikij NN, Obrosova IG, Efimov AS, Babicheva EI, Sokil OP. Nicotinamide coenzymes in the regulation of cellular metabolism in various types of diabetes. Vopr Med Khim 1992; 38: 45-52.
41. Glock GE, McLean P. Effects of hormones on levels of oxidized and reduced diphosphopyridine nucleotide and triphosphopyridine nucleotide in the liver and diaphragm. Biochem J 1955; 61: 397-402.
42. Song HP, Han XY, He Y, Rang TB, Wu HW. Activities of aldose reductase, ATPases, and nucleotide concentrations of erythrocytes in patients with type 2 (non-insulin-dependent) diabetes mellitus. Chin Med J Engl 1991; 104: 818-824.
43. Williamson DH, Mayor F, Veloso D, Page MA. Effects of nicotinic acid and related compounds on ketone body metabolism. In Metabolic Effects of Nicotinic Acid and its Derivatives. Gey KF, Carlson LA (eds). Bern: Hans Huber, 1971; 227-236.
44. Badawy A, Evans M. The regulation of rat liver tryptophan pyrrolase activity by reduced nicotinamide-adenine dinucleotide (phosphate). Biochem J 1976; 156: 381-390.
45. Paul P, Issekutz B Jr, Miller HI. Interrelationship of free fatty acids and glucose metabolism in the dog. Amer J Physiol 1966; 211: 1313-1320.
46. Balasse EO, Neef MA. Influence of nicotinic acid on the rates of turnover and oxidation of plasma glucose in man. Metabolism 1973; 22: 1193-1204.
47. Benito M, Moreno FJ, Medina JM, Mayor F. Operation of the glucose-fatty acid cycle after glycogenolysis induced by treatment with nicotinic acid. Arch Biochem Biophys 1978; 188: 21-25.
48. Carlson LA, Nye ER. Acute effects of nicotinic acid in the rat. I. Plasma and liver lipids and blood glucose. Acta Med Scand 1966; 179: 453-461.
49. Davidson MB, Bernstein JM. The effect of nicotinic acid on growth hormone-induced lipolysis and glucose intolerance. J Lab Clin Met 1973; 81: 568-576.
50. Mirsky A, Perisutti G, Jinks R. The hypoglycaemic action of metabolic derivatives of L-tryptophan by mouth. Endocrinology 1957; 60: 318-324.
51. Gross RC, Carlson LA. Metabolic effects of nicotinic acid in acute insulin deficiency in the rat. Diabetes 1968; 17: 353-361.
52. Carlson LA, Östman J. Inhibition of the mobilization of free fatty acids from adipose tissue in diabetes. I. Effect of nicotinic acid on the alloxan-diabetic state in rats. Acta Med Scand 1965; 177: 631-637.
53. Alesker EM. Influence of nicotinic acid on diabetes mellitus. Therap Arkh 1948; 20: 62-76.
54. Björntorp P. Inhibition of lipase activation in rat epididymal fat pads in vitro. Amer J Physiol 1966; 210: 733-736.
55. Ho RJ, Jeanrenaud B. Insulin-like action of ouabain I. Effect on carbohydrate metabolism. Biochim Biophys Acta 1967; 144: 61-73.
56. Carlson LA. Nicotinic acid: its metabolism and its effects on plasma free fatty acids. In Metabolic Effects of Nicotinic Acid and its Derivatives. Gey KF, Carlson LA (eds). Bern: Hans Huber Verlag, 1971; 158-165.
57. Exton JH, Lewis SB, Park CR. Examination of in vitro effects of nicotinic acid on basal and hormone-stimulated glycogenolysis, gluconeogenesis, ureogenesis and ketogenesis in the isolated perfused rat liver. In Metabolic Effects of Nicotinic Acid and its Derivatives. Gey KF, Carlson LA (eds). Bern: Hans Huber Verlag, 1971; 851-859.
58. Neuwahl FJ. Action of nicotinic acid on carbohydrate metabolism. Lancet 1943; Sept 18: 348-351.
59. Yamamoto H, Okamoto H. Protection by picolinamide, a novel inhibitor of poly(ADP-ribose)-synthetase, against both streptozotocin-induced depression of proinsulin synthesis and reduction of NAD content in pancreatic islets. Biochem Biophys Res Commun 1980; 95: 474-481.
60. Gaut ZN, Pocelinko R, Solomon HM, Thomas GB. Oral glucose tolerance plasma insulin, and uric acid excretion in man during chronic administration of nicotinic acid. Metabolism 1971; 20: 1031-1035.
61. Kahn SE, Beard JC, Schwartz MW, et al. Increased β-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes 1989; 38: 562-568.
62. Nikkilä EA, Miettinen TA. Nicotinic acid and gluconeogenesis in man. In Metabolic Effects of Nicotinic Acid and its Derivatives. Gey KF, Carlson LA (eds). Bern: Hans Huber Verlag, 1971; 753-755.
63. Molnar GD, Berge KG, Rosevear JW, McGuckin WF, Achor RWP. The effect of nicotinic acid in diabetes mellitus. Metabolism 1964; 13: 181-190.
64. Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 1990; 264: 723-726.
65. Neumann R, Rappold E, Pohl-Marld H. Treatment of polymorpous light eruption with nicotinamide: a pilot study. Br J Dermatol 1986; 115: 77-80.
66. Bingley PJ, Caldas G, Bonfanti R, Gale EAM. Nicotinamide and insulin secretion in normal subjects. Diabetologia 1993; 36: 675-677.
67. Neumann R. Reply. Br J Dermatol 1987; 116: 277
68. Pozzilli P, Kolb H, Browne PD, The Nicotinamide Trialists. Meta-analysis of nicotinamide treatment in patients with recent-onset IDDM. Diabetes Care 1996; 19: 1357-1363.
69. Polo V, Saibene A, Pontiroli AE. Nicotinamide improves insulin secretion and metabolic control in lean type 2 diabetic patients with secondary failure to sulphonylureas. Acta Diabetol 1998; 35: 61-64.
70. Mauer SM, Steffes MW, Brown DM. The kidney in diabetes. Amer J Med 1981; 70: 603-612.
71. McLennan SV, Fischer EJ, Yue DK, Turtle JR. High glucose concentration causes a decrease in mesangium degradation. A factor in the pathogenesis of diabetic nephropathy. Diabetes 1994; 43: 1041-1045.
72. Makita Z, Radoff S, Rayfield EJ, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991; 325: 836-842.
73. Spiro RG. Search for a biochemical basis of diabetic microangiopathy. Diabetologia 1976; 12: 1-14.
74. Anderson JW, Stowring L. Glycolytic and gluconeogenic enzyme activities in renal cortex of diabetic rats. Amer J Physiol 1973; 224(4): 930-936.
75. Sochor M, Baquer NZ, McLean P. Glucose overutilization in diabetes: evidence from studies on the changes in hexokinase, the pentose phosphate pathway and glucoronate-xylulose pathway in rat kidney cortex in diabetes. Biochem Biophys Res Commun 1979; 86: 32-39.
76. Gabbay KH. The sorbitol pathway and the complications of diabetes. N Engl J Med 1973; 288: 831-836.
77. Wahl P, Deppermann D, Deschner W, Fuchs E, Rexroth W. The metabolism of the isolated renal glomerulus and its basement membranes. In Vascular and Neurological Changes in Early Diabetes. Camerini-Davalos RA, Cole HS (eds). New York: Academic Press, 1973; 147-153.
78. Petrash JM, Tarie I, Wilson DK, Quiocho FA. Aldose reductase catalysis and crystallography. Insights from recent advances in enzyme structure and function. Diabetes 1994; 43: 955-959.
79. Frank RN. (Perspective in diabetes). The aldose reductase controversy. Diabetes 1994; 43: 169-172.
80. Tilton RG, Chang K, Nyengaard JR, Van den Enden M, Ido Y, Williamson JR. Inhibition of sorbitol dehydrogenase: effects on vascular and neural dysfunction in streptozocin-diabetic rats. Diabetes 1995; 44: 234-242.
81. Reichard P, Nilsson B-Y, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993; 329: 304-309.
82. Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 1993; 341: 1306-1309.
83. The Diabetes Control Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
84. Ohkubo Y, Kishikawa H, Araki E, et al. Good glycaemic control can reduce complications of type 2 diabetes. Diabet Res Clin Pract 1995; 28: 103-117.
85. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995; 18: 258-268.
86. Carpenter A-M, Goetz FC, LeCompte PM, Williamson JR. Glomerulosclerosis in type 2 (non-insulin-dependent) diabetes mellitus: relationship to glycemia in the University Group Diabetes Program (UGDP). Diabetologia 1993; 36: 1057-1063.
87. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
88. Mehler AH, McDaniel EG, Hundley JM. Changes in the enzymatic composition of liver I. Increase of picolinic carboxylase in diabetes. J Biol Chem 1958; 232: 323-330.
89. Mehler AH, Yano K, May EL. Nicotinic acid biosynthesis: control by an enzyme that competes with a spontaneous reaction. Science 1964; 145: 817-819.
90. Ikeda M, Tsuji H, Nakamura S, Arata I, Nishizuka Y, Hayaishi O. Studies on the biosynthesis of nicotinamide adenine dinucleotide. II. A role of picolinic carboxylase in the biosynthesis of nicotinamide adenine dinucleotide from tryptophan in mammals. J Biol Chem 1965; 240: 1395-1401.
91. Oka M, Leppänen VVE. Metabolism of tryptophan in diabetes mellitus. Acta Med Scand 1963; 173: 361-364.
92. Calandra P. Identification of tryptophan metabolites in the healthy epidermis of diabetics. Acta Diabet Lat 1977; 14: 26-37.
93. Knowles HC Jr. Long term juvenile diabetes treated with unmeasured diet. Trans Assoc Amer Fys 1971; 85: 95-101.
94. Oakley WG, Pyke DA, Tattersall RB, Watkins PJ. Long term diabetes. Quarterly Journal of Medicine, New Series, XLIII, 1974; 169: 145-156.
95. Lithner F. Diabetes of excessively long duration with only minor manifestations of long term diabetic complications. Acta Med Scand 1978; 203: 143-144.
96. Deckert T, Poulsen JE, Larsen M. Prognosis of diabetics with diabetes onset before the age of thirty-one. Diabetologia 1978; 14: 363-370.
97. Seaquist E, Goetz FC, Rich S, Barbosa J. Familia clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989; 320: 1161-1165.
98. Bauer M, Levan NE. Diabetic dermangiopathy. A spectrum including pigmented pretibial patches and necrobiosis lipoidica diabeticorum. Br J Dermatol 1970; 83: 528-535.
99. Pozzilli P, Andreani D. The potential role of nicotinamide in the secondary prevention of IDDM. Diabetes Metab Rev 1993; 9: 219-230.
100. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm ischaemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988; 223: 405-418.
101. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in coronary drug project patients: Long-term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245-1255.
102. Cashin-Hemphill , Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA 1990; 264: 3013-3017.
103. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289-1298.
104. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963; i: 785-789.
105. Björntorp P, Östman J. Human adipose tissue dynamics and regulation. Adv Metab Dis 1971; 5: 277-327.
106. Walldius G, Norbeck H-E, Wahlberg G. Low fatty acid and glucose incorporation into adipose tissue in hypertriglyceridemia: A removal defect. In Metabolic Risk Factors in Ischemic Cardiovascular Disease. Carlson LA, Pernow B (eds). New York: Raven Press, 1982; 225-238.
107. Goldsmith G, Miller N, Unglaub W. Efficiency of tryptophan as a niacin precursor in man. J Nutr 1961; 73: 172-176.
108. Dalton C, Vantrabert TC, Dwyer JX. Hypolipidemic effects of nicotinamide in the rat arising from its transformation to nicotinic acid. In Metabolic Effects of Nicotinic Acid and its Derivatives. Gey KF, Carlson LA (eds). Bern: Hans Huber, 1971; 65-75.
109. Gopalan C, Jaya Rao KS. Pellagra and amino acid imbalance. Vitamins and Hormones 1975; 33: 505-528.